An expanded access record providing Ruxolitinib in Primary Myelofibrosis (PMF), Post Polycythemia Myelofibrosis (PPV MF) and Thrombocythemia Myelofibrosis (PET-MF), sponsored by Novartis Pharmaceuticals. Available. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2025-11-18.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Expanded access
The purpose of this registration is to list Managed Access Programs (MAPs) related to INC424, Ruxolitinib
CINC424A2405 - No longer available- Managed Access Program (MAP) Cohort Treatment Plan CINC424A2405 to provide access to Ruxolitinib for patients with Primary Myelofibrosis (PMF) or Post Polycythemia Myelofibrosis (PPV MF) or Post-Essential Thrombocythemia Myelofibrosis (PET-MF)
CINC424A2001M - No longer available - Ruxolitinib Managed Access Program (MAP) for patients diagnosed with severe/very severe COVID-19 illness
CINC424B2002I - No longer available- Managed Access Program (MAP) Cohort Treatment Plan CINC424B2002I to provide access to Ruxolitinib for patients with Polycythemia Vera (PV)
CINC424C2001M - Available - Managed Access Program (MAP) Cohort Treatment Plan CINC424C2001M to provide access to ruxolitinib for steroid refractory acute and chronic Graft versus Host Disease (SR aGVHD and SR cGHVD).
625 studies on the registry are indexed under Primary Myelofibrosis; 124 are open to participants now.
Browse Primary Myelofibrosis studies →Novartis Pharmaceuticals is the lead sponsor of 2,718 studies on the registry; 221 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 438 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion criteria
Patients receive Ruxolitinib
Also known as: INC424
No study locations are listed for this record.
Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.
Contact the providerGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.